Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6827498 | 0.76 | MAPT (0.38) | MITFMAPTLMNAHTTATM | |
| SCHEMBL1770982 | 0.74 | MAPT (0.39) | MITFMAPTLMNAHTTATM | |
| SCHEMBL2795974 | 0.74 | CYP2A6 (0.44) | MITFMAPTLMNAHTTATM | |
| SCHEMBL1193736 | 0.74 | IDO1 (0.44) | MITFMAPTLMNAHTTATM | |
| SCHEMBL5784218 | 0.74 | MAPT (0.53) | MITFMAPTLMNAHTTRAB9A | |
| SCHEMBL450730 | 0.74 | CHKA (0.46) | MITFMAPTLMNAHTTRAB9A | |
| SCHEMBL633918 | 0.74 | KMT2A (0.39) | MITFMAPTLMNAHTTRAB9A | |
| SCHEMBL633559 | 0.71 | RAB9A (0.36) | MITFMAPTLMNAHTTRAB9A | |
| SCHEMBL3367760 | 0.71 | RAB9A (0.61) | MITFMAPTHTTRAB9ARCE1 | |
| Quindoxin SCHEMBL29462546 | 0.70 | ATM (0.43) | MITFMAPTLMNAHTTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069271-A1 | Quinolone compounds for use in treating viral infections | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
| EP-1244629-A2 | QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS | GLAXO GROUP LIMITED (GB) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001046150-A2 | QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069271-A1 | Quinolone compounds for use in treating viral infections | IRF3, MAVS, NQO2 | MITF 2650/4885MAPT 2817/4885LMNA 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.